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Abstract 
Background: For over a decade, Cambodia has implemented a number of policies and innovative strategies to 
increase access to quality malaria case management services and address the drivers of multi-drug resistance. This 
paper utilizes outlet survey trend data collected by the ACTwatch project to demonstrate how changes in Cambodian 
policy and strategies have led to shifts in anti-malarial markets.
Methods: Anti-malarial ACTwatch outlet surveys were conducted in Cambodia in 2009 (June–July), 2011 (June–
August) and 2013 (September–October). A census of all outlets with the potential to sell or distribute anti-malarials 
was conducted within a nationally representative sample of communes. Drug information, sales/distribution in the 
previous week, and retail price were collected for each anti-malarial in stock. Information on availability of malaria 
blood testing was also collected.
Results: A total of 7833 outlets were enumerated in 2009, 18,584 in 2011, and 16,153 in 2013. The percentage 
of public health facilities with at least one anti-malarial in stock on the day of the survey increased between 2009 
(65.8 %) and 2011 (90.0 %) and remained high in 2013 (82.0 %). Similar trends were found for village malaria workers 
(VMW). Overall, private sector availability of anti-malarials declined over time and varied by outlet type. By 2013 most 
anti-malarial stocking public health facilities (81.5 %), VMW (95.4 %), private for-profit health facilities (64.8 %), and 
pharmacies (71.9 %) had the countries first-line artemisinin-based combination therapy (ACT) treatment in stock. In 
2013, 60 % of anti-malarials were delivered through the private sector, 40 % through the public sector, and the most 
common anti-malarial to be sold or distributed was the first-line ACT, comprising 62.8 % of the national market share. 
Oral artemisinin monotherapy, which had accounted for 6 % of total anti-malarial market share in 2009, was no longer 
reportedly sold/distributed in 2013. Malaria blood testing availability remained high over time among public facilities 
and VMW, with availability over 90 % in 2011 and 2013. Moderate availability was observed in the private sector.
Conclusions: Continued implementation of successful public and private sector strategies in support of evolving 
malaria drug treatment policies will be important to protect the efficacy of anti-malarial medicines and ultimately 
facilitate malaria elimination in Cambodia by 2025.
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Background
Cambodia has seen a general decline in clinically diag-
nosed cases of malaria and case fatality over the past 
decade, coupled with a significant and steady decrease in 
overall malaria prevalence [1]. Having achieved substan-
tial reductions in malaria morbidity and mortality since 
2001, Cambodia is now making the shift from a malaria 
control programme to a phased elimination strategy [2, 
3]. The Cambodian National Strategic Plan for elimina-
tion of malaria aims to ensure that there are no malaria 
deaths by 2020 and Plasmodium falciparum malaria is 
eliminated by 2020 with Plasmodium vivax and other 
forms of malaria eliminated by 2025. Malaria treatment 
effectiveness and elimination rely on the continued effi-
cacy of artemisinin-based combination therapy (ACT), 
which has been the first-line treatment for P. falciparum 
malaria in Cambodia since 2000.
The malaria situation is complex in Cambodia due 
to variance in malaria burden by geographic area and 
mobility of at-risk populations. Moreover, Cambo-
dia is well documented as the epicenter of multi-drug 
resistant malaria [4] which poses a major impediment 
to disease containment and eradication. Delayed para-
site clearance following treatment with artemisinin 
and artemisinin-based combination was first detected 
in western Cambodia in 2007, and is now confirmed 
across the Greater Mekong Subregion (GMS) includ-
ing foci in Laos, Myanmar, Thailand and Vietnam [3, 
5–8]. As resistance to earlier anti-malarial medicines 
spread from this region to Africa and other parts of 
Asia through parasite migration, there is a serious con-
cern that a similar scenario may occur with artemisinin 
resistance [5, 9–11]. The loss of ACT to resistance is 
highly problematic given there is no other treatment 
available with the same efficacy and tolerability [12], 
lending to the fear of a malaria resurgence that could 
undo a decade of progress in control as well as threaten 
the feasibility of elimination [13].
Cambodia’s malaria campaigns and interventions
In response to the development of multi-drug resistant 
malaria, Cambodia designed and implemented a num-
ber of policy and strategy changes to improve coverage 
of appropriate case management (see Fig. 1). Dating back 
to 2000, Cambodia became the first country to switch 
its first-line national malaria treatment policy for falci-
parum malaria to an ACT of artesunate and mefloquine 
(ASMQ) and to stipulate diagnostic testing prior to treat-
ment. Since 2000, the Cambodian government provided 
first-line ACT for free in public health facilities and para-
sitological diagnosis was promoted through the introduc-
tion of rapid diagnostic tests (RDT) and strengthening 
the capacity of skilled microscopists.
Private sector engagement in the provision of diagno-
sis and ACT treatment for malaria is central given that 
data confirms that most febrile people in Cambodia 
seek treatment exclusively from private facilities [14, 
15]. In lieu of this, since 2002 a social marketing pro-
gramme of subsidized first-line ACT and RDT was ini-
tiated through Population Services International (PSI) to 
improve the availability and quality of malaria diagnosis 
and treatment in this sector [30, 31]. The social market-
ing programme was designed to directly mirror the pub-
lic sector, by procuring the same ACT and RDT as the 
national programme. As a means to ensure compliance 
with national treatment guidelines among private pro-
viders, sales representatives and medical detailers were 
also employed to provide training, counseling, and sup-
port on the appropriate use of ACT and RDT. By 2013, 
the PSI social marketing programme was actively reach-
ing around 1500 outlets per month through sale repre-
sentatives and around 500 pharmacy operated facilities 
through medical detailers.
In 2004, the Cambodia National Centre of Entomol-
ogy, Parasitological and Malaria (CNM) piloted the Vil-
lage Malaria Worker (VMW) programme to provide 
diagnosis and treatment among remote communities 
through a community-based health workforce, which 
was expanded and extended in 2009 to the highest-risk 
villages and remote areas. By 2014 the VMW programme 
was providing early diagnosis and treatment for malaria 
to over 1,600 villages and 130 mobile communities across 
17 provinces [16].
Over the years there have been a series of changes in 
the National Treatment Guidelines following recommen-
dations from the World Health Organization (WHO) 
to change treatments when resistance to the drug is 
detected. In 2008, due to high failure rates with ASMQ, 
the first-line treatment for uncomplicated P. falciparum 
malaria was changed from co-blistered ASMQ to fixed-
dose dihydroartemisinin-piperaquine (DHA-PPQ) in 
specific areas of the country where artemisinin resistance 
had been identified; DHA-PPQ became the nationwide 
first-line treatment for both P. falciparum malaria and P. 
vivax malaria in 2010.
In 2009, the Cambodian government took signifi-
cant steps to regulate the pharmaceutical industry, and 
banned the importation, manufacturing, registration and 
sale of oral artemisinin monotherapies [12]. To enforce 
the move, the Ministry of Health (MoH) created a new 
cadre of law enforcement officers, providing them with 
authority to crack down on illegal and substandard medi-
cines. This included the recruitment of 200 new offi-
cials, also known as the ‘Justice Police’, as well as training 
of over 400 police to enable authorities to identify oral 
artemisinin monotherapy and enforce the ban within 
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the Cambodian marketplace. The government also used 
mystery clients to further identify outlets selling any 
oral artemisinin monotherapy, and instituted a system 
of licensing drug outlets and using the Justice Police to 
regularly check for and confiscate fake, substandard or 
banned drugs. In addition, an international collaboration 
led by INTERPOL succeeded in shutting down a major 
Chinese producer of fake artemisinin that had flooded 
the markets throughout the GMS. These efforts were also 
supported with a communication campaign to educate 
private providers about the dangers of oral artemisinin 
monotherapy.
Since the original crack down of unlicensed private 
providers in 2009, CNM also partnered with the Ministry 
of Interior Anti-Economic Crime Police and the Depart-
ment of Drugs and Food to intensify enforcement and 
regulatory activities in the private health sector [17]. Pri-
vate outlets including pharmacies and drug shops were 
progressively registered, and it was estimated that unli-
censed outlets in the country decreased from 1081 in 
November 2009 to only 28 in July 2011 [16].
In 2011, as a means to further engage and strengthen 
the private and public sector, CNM and the MoH final-
ized operational guidelines for implementing public 
private partnership (PPM) programme activities [17]. 
Similar to PSI’s social marketing programme, the PPM 
strategy provided ACT and RDT commodities, training 
to improve private providers’ case management skills, as 
well as routine supervision visits. Coordination between 
the public and private sectors was also advanced: a pro-
vider database of licensed outlets was created and rou-
tine malaria case-load data collection from all outlets was 
prioritized. A gradual expansion of the PPM programme 
led to national scale up in 2012, in collaboration with PSI 
and University Research Council (URC), and has now 
been extended to over 1000 providers registered across 
most of the malaria endemic districts. By the end of 2013, 
there were 10 Operational Districts (OD) under CNM, 3 
under URC and 9 under PSI for the PPM programme.
There is a lack of documentation on the extent to which 
these changes to malaria case management policy and 
strategy have led to changes in the performance of Cam-
bodia’s anti-malarial public and private sector markets. 
This is of particular importance given Cambodia’s recent 
commitment to eliminate all types of malaria by 2025 and 
persistent work over the past decade to contain and pre-
vent the spread of artemisinin resistance. The primary 
aim of this paper is to use ACTwatch outlet survey trend 
data to demonstrate how changes in Cambodian policy 
have led to shifts in anti-malarial markets over time. Spe-
cifically the paper presents evidence from ACTwatch 
outlet surveys conducted in 2009, 2011, 2013 regard-
ing the availability and market share of anti-malarials 
and malaria testing availability in the public and private 
sector.
Methods
The ACTwatch project is a multi-country research pro-
ject implemented by PSI and was launched in 2008. The 
goal of the ACTwatch project is to provide timely, rel-
evant, and high quality anti-malarial market evidence 
to inform and monitor national and global policy, strat-
egy, and funding decisions for improving malaria case 
management. Standardized tools and approaches are 
Fig. 1 Timeline of events in Cambodia (2000–2014)
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employed to provide comparable data across countries 
and over time. These approaches have been documented 
elsewhere in detail [15, 18–21]. One key component 
of the project is to collect outlet survey data to under-
stand anti-malarial supply side issues, and to address 
key indicators such as: what types of outlets stock anti-
malarials, what is the market share of different classes 
of anti-malarials and how does this differ between the 
public and private sector. Indicators are typically pre-
sented for both the public and private sector. Through-
out the years, the project has expanded to include the 
same information on a full range of RDT. In short, the 
ACTwatch outlet survey studies are designed to provide 
contemporary malaria market data from all public and 
private sector outlets providing malaria testing or treat-
ment to patients or consumers.
Sample
As part of the ACTwatch project, three rounds of nation-
ally-representative cross-sectional malaria medicine 
outlet surveys were conducted in Cambodia 2009 (June–
July); 2011 (June–August); and 2013 (September–Octo-
ber). Data collection coincided with the Cambodia rainy 
season when malaria transmission is highest, generally 
beginning in late May and ending in December.
Design and sampling
A nationally representative sample of outlets provid-
ing anti-malarials to patients was selected for each sur-
vey round. Each survey was stratified to deliver separate 
estimates for the zones defined by CNM to guide policies 
and programmes to address artemisinin resistance. Non-
malaria endemic areas were excluded from the sampling 
frame.
The study was powered to detect a minimum of a 
20-percentage point change in availability of first-line 
ACT among anti-malarial stocking outlets between each 
round. Based on the desired number of anti-malarial 
stocking outlets within each round and assumptions 
about number of anti-malarial stocking outlets per com-
mune, a sample of communes was selected within each 
research domain with probability proportional to popula-
tion size.
Within each selected commune all outlets with the 
potential to provide anti-malarials to patients were sam-
pled (see Table  1 for a description of the outlet types). 
Outlets that did not serve the general public (e.g. mili-
tary facilities) were excluded from the study. The bound-
ary for the census of public health facilities was extended 
to the district level for over-sampling of these outlet 
types.
A screening questionnaire was administered to all 
outlets with the potential to distribute anti-malarials to 
patients. Outlets were eligible for a provider interview 
and malaria product audit if they met at least one of the 
study criteria: (1) one or more anti-malarials reportedly 
in stock the day of the survey; (2) one or more anti-malar-
ials reportedly in stock within the 3  months preceding 
the survey. A new eligibility criteria was included in the 
2013 survey to screen for the provision of malaria blood 
testing (microscopy or RDT).
Training and fieldwork
For all survey rounds interviewer training was provided 
over a minimum of 6  days, using standardized training 
materials. The training was implemented in collabora-
tion with the CNM and focused on outlet identification, 
informed consent procedures, and the procedures for 
completing the questionnaire. An additional two-
day training was provided for quality controllers and 
supervisors.
Field workers were provided with a list of the selected 
communes and maps that illustrated their administra-
tive boundaries, in addition to lists of public health facili-
ties and pharmacies obtained from relevant authorities. 
Snowball sampling was also used by field workers to 
identify facilities that were not on the official lists. In 
each selected cluster, fieldworkers conducted a census of 
all outlets that had the potential to provide anti-malarials 
Table 1 Outlet types and definitions
Sector and facility type Outlet types
Public Sector
 Public health facilities Referral hospitals, health centers, sub-health 
centers, former district hospitals, and health 
posts
 Village Malaria Worker VMW are community-based volunteers 
equipped with anti-malarial treatment and 
malaria blood testing
Private Sector
 Private for-profit health 
facilities
Private for-profit health facilities including 
private hospitals, clinics, cabinets and diag-
nostic laboratories
 Pharmacies Pharmacies are licensed and regulated by 
a national regulatory authority, and are 
staffed by pharmacists and qualified health 
practitioners. These include clinical pharma-
cies, pharmacies, depot A, and depot B
 Drug stores Drug stalls in rural markets and shops that pri-
marily sell medicines. These outlets are not 
guaranteed to be staffed by qualified health 
dispensers/practitioners and not typically 
licensed by a national regulatory authority
 General retailers Grocery stores and village shops
 Itinerant drug vendors Mobile providers found primarily in rural 
areas, typically working within a radius of 
their home. They are not registered with any 
national regulatory authority
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by traveling systematically throughout the entire com-
mune and approaching all outlets eligible for screening. 
For each outlet that was identified during the census, the 
outlet type and location were noted, along with its lon-
gitude and latitude coordinates (using hand-held global 
positioning units). A fieldworker then approached the 
outlet’s main provider or owner and invited him or her 
to participate in the study. Providers who agreed to par-
ticipate were asked the screening questions to determine 
eligibility. An interview with the staff member who was 
most likely to sell or prescribe medications was con-
ducted. The interview was carried out in Khmer.
During data collection, approximately 80 % of all ques-
tionnaires were reviewed by the team supervisor and 
15–20 % of all outlets were revisited by a supervisor or/
and quality controllers for quality control checks.
Measures
A structured questionnaire, which included an anti-
malarial audit and RDT audit, was used for the outlet 
survey interviews. Following informed consent proce-
dures, an audit of all available anti-malarial medicines 
and RDT was first conducted. To complete the audit, 
providers were asked to show the interviewer all anti-
malarial brands that were currently available in the out-
let. Using the audit sheet, the interviewer then recorded 
the product information for each anti-malarial brand 
in the outlet, including formulation, brand name, active 
ingredients and strengths, manufacturer and country of 
manufacture. Following this, the provider was asked, for 
each anti-malarial in stock, the unit cost of that medicine 
and amount distributed to individual patients or con-
sumers in the last week (see Additional file 1 for an exam-
ple of the audit sheet). A similar pattern was repeated for 
outlets stocking RDT in 2011 and 2013, using the RDT 
audit. The RDT audit information included brand name, 
manufacturer, country of manufacture, reported sale/dis-
tribution in the week preceding the survey, retail price, 
and wholesale price (see Additional file 2 for an example 
of the RDT audit sheet). In addition to the anti-malar-
ial and RDT product audit, a series of questions were 
administered to the senior-most provider responsible for 
diagnosis and/or medicine prescription. The questions 
assessed malaria case management knowledge and prac-
tices as well as provider training and qualifications as well 
as the availability of malaria microscopy.
The 2009, 2011 and 2013 outlet survey protocols 
received ethical approval from the National Ethics Com-
mittee for Health Research in Cambodia. Provider inter-
views and product audits were completed only after 
administration of a standard informed consent form and 
provider consent to participate in the study. Providers 
had the option to end the interview at any point during 
the study. Standard measures were employed to maintain 
provider confidentiality and anonymity.
Data analysis
Double data entry was conducted using Microsoft Access 
(Microsoft Corporation, Redmond, Washington, USA) 
with built-in range and consistency checks. Entered data 
were triangulated with questionnaires, field supervision 
notes and daily activity logs filled by each interviewer in 
the field. Data were analysed across survey rounds using 
Stata (StataCorp College Station, TX). Stata survey set-
tings were used to account for the stratified and clustered 
sampling strategy. Results were adjusted by sampling 
weights. Sampling weights were calculated as the inverse 
of the probability of commune selection.
Standard indicators were constructed according to def-
initions applied across the ACTwatch project and have 
been described elsewhere [20, 21]. Briefly, anti-malarials 
identified during the outlet drug audit were classified 
according to information on drug formulation, contents 
and strengths with supporting information including 
brand or generic name and manufacturer. Among outlets 
stocking anti-malarials (i.e. those outlets that had at least 
one anti-malarial in stock on the day of survey), variables 
were created to indicate availability by type, including 
the broad category of ACT, as well as specific categories 
including all ASMQ, DHA-PPQ, oral artemisinin mono-
therapy, non-oral artemisinin monotherapy, and non-
artemisinin monotherapy (such as chloroquine).
Availability of anti-malarials was measured as the pro-
portion of outlets with at least one anti-malarial in stock, 
among all censused outlets. Availability was determined 
according to the anti-malarial packages that were found 
in the outlet and then audited. The availability of specific 
anti-malarial categories, restricted to those outlets that 
had anti-malarials in stock, was also calculated. Thus, 
for example, the availability of ACT was measured as the 
proportion of outlets stocking ACT, among all outlets 
with at least one anti-malarial in stock.
The volume of the anti-malarials recorded in the drug 
audit were standardized using the adult equivalent treat-
ment dose (AETD) to allow meaningful comparisons 
between anti-malarials with different treatment courses. 
The AETD is defined as the amount of active ingredient 
required to treat an adult weighing 60  kg according to 
WHO treatment guidelines [22]. Provider reports on the 
amount of the drug sold or distributed during the week 
preceding the survey were used to calculate volumes 
according to type of anti-malarial: ASMQ, DHA-PPQ, 
other ACT, oral artemisinin monotherapy, non-oral arte-
misinin monotherapy and non-artemisinin monother-
apy. The volume of each drug is therefore the number of 
AETDs that were reportedly sold/distributed during the 
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week preceding the survey. Measures of volume include 
all dosage forms to provide a complete assessment of 
anti-malarial market shares to the consumer or patient. 
Audited anti-malarials with missing data required to 
calculate AETD (strength, amount distributed) were 
excluded from volumes estimation. This measure of anti-
malarial volumes was then used to describe the ACT-
watch indicator on market share, and is subsequently 
referred to as this.
Results
A total of 7833 outlets in 2009, 18,584 in 2011 and 16,153 
in 2013 were approached to participate in the surveys. 
Of these, over 95  % of outlets were screened for stock-
ing anti-malarials across the three survey rounds. Among 
screened outlets, 11.5 % of outlets in 2009, 8.5 % of out-
lets in 2011 and 9.2 % of outlets in 2013 met the screen-
ing criteria and were administered the questionnaire 
(Table  2). The total number of anti-malarials audited 
were as follows: 2009, N  =  2051; 2011, N  =  2598 and 
2013, N = 2811. An increase is observed in the number of 
RDT audited over time (2009, N = 653; 2011, N = 1005; 
2013, N = 1267).
Anti‑malarial availability
Figure 2 shows trends in the availability of anti-malarials 
as the proportion of all surveyed outlets. The percentage 
of public health facilities with at least one anti-malar-
ial in stock on the day of the survey increased between 
2009 (65.8  %) and 2011 (90.0  %) and remained high 
in 2013 (82.0  %). Similar trends were found for VMW 
(2009  =  57.7  %; 2011  =  93.7  %; and 2013  =  88.1  %). 
Overall, private sector availability of anti-malarials 
declined over time and varied by outlet type, with private 
for-profit health facilities and pharmacies more likely 
to stock anti-malarials than other private sector outlet 
types. In 2013, just over half of the pharmacies (53.2 %) 
and 45.5 % of private for-profit facilities had anti-malar-
ials in stock on the day of survey. Stocking rates by drug 
stores, general retailers and itinerant drug vendors were 
less than 20 %.
Figure  3 shows the relative distribution of all outlets 
that had at least one anti-malarial in stock, over time. 
Results show a change in the diversity of outlet types 
stocking anti-malarials. Private sector market composi-
tion shifted over time towards increasing distribution 
through the private for-profit health facility and phar-
macy outlet types and declining contribution from drug 
stores, general retailers, and itinerant drug vendors. Pri-
vate for-profit facilities increased from 8 % of all outlets 
stocking anti-malarials in 2009 to 20  % in 2013. Simi-
larly, pharmacies increased from 3 % of all outlets stock-
ing anti-malarials in 2009 to 17  % in 2013. In contrast, 
declines were observed for general retailers, which con-
stituted 34 % of all outlets stocking anti-malarials in 2009 
and only 9  % of outlets in 2013. Similar declines were 
observed for drugs stores, which comprised of 15  % of 
all anti-malarial stocking outlets in 2009 and only 10 % in 
2013.
Figure  4 show trends in the availability of different 
classes of the two first-line ACT (ASMQ and DHA-PPQ) 
as the proportion of outlets with at least one anti-malarial 
Table 2 Outlet sample composition 2009, 2011 and 2013
n/a screening questions regarding the availability of blood testing were not included in the 2009 and 2011 surveys
2009 2011 2013
Among outlets approached N = 7833 N = 18,584 N = 16,153
 Proportion that were screened 95.9 % 96.6 % 97.5 %
Among all outlets screened N = 7513 N = 17,923 N = 15,755
 Proportion that met the screening criteria (%) 11.5 8.5 9.2
 Proportion that were interviewed (%) 11.5 8.4 9.1
Among outlets screened N N N
 Number that meet the screening criteria
  Anti-malarial(s) in stock 865 1283 1221
  Anti-malarial(s) out of stock but reportedly in stock in the previous 3 months 7 246 123
  Anti-malarial(s) not in stock but blood testing available n/a n/a 112
  Total 872 1529 1456
 Number that were interviewed
  Anti-malarial(s) in stock 863 1270 1215
  Anti-malarial(s) out of stock but reportedly in stock within 3 months 7 246 123
  Anti-malarial(s) not in stock but blood testing available n/a n/a 111
  Total 870 1516 1449
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in stock. In 2009 when ASMQ was the first-line treat-
ment for Cambodia, with the exception of resistance con-
tainment areas of the country (for which DHA-PPQ had 
been the first-line since 2008), availability was very high 
in anti-malarial stocking public health facilities (97.5 %) 
and VMW (87.6 %), as well as private for-profit facilities 
(87.1  %), pharmacies and drug stores (84.0  %). ASMQ 
was less available among general retailers (40 %) and itin-
erant drug vendors (~60 %) in 2009.
After the change in the national first-line treatment 
from ASMQ to DHA-PPQ in 2010, ASMQ availability 
declined across all outlet types, however availability of 
DHA-PPQ was modest among anti-malarial stocking 
public health facilities (23.5 %), VMW (46.4 %) and was 
less than 10  % across all private sector outlets in 2011 
(Fig.  5). By 2013, significant increases were observed in 
DHA-PPQ availability across all anti-malarial stock-
ing outlet types. The majority of anti-malarial stocking 
public health facilities had DHA-PPQ in stock (81.5 %), 
as did VMW (95.4  %), with private health facilities and 
pharmacies also showing high DHA-PPQ availability 
(64.8 and 71.9 % respectively). DHA-PPQ availability was 
lower among anti-malarial stocking drug stores (42.0 %), 
general retailers (13.7  %), and itinerant drug vendors 
(46.5 %).
The percentage of private sector anti-malarial stocking 
outlets with oral artemisinin monotherapy in stock on 
the day of the survey decreased over time (2009 = 20.2 %; 
2011 = 4.2 %; and 2013 = 1.6 % (Fig. 6). In 2013, availabil-






























Fig. 3 Trends in the market distribution among anti-malarial stocking outlets (2009 N = 652 outlets; 2011 N = 1001 outlets; 2013 N = 792 outlets)
N for the graph is as follows:



































































Fig. 2 Percentage of all outlets with at least one anti-malarial in stock on the day of survey
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health facilities, and 5.2 % among itinerant drug vendors. 
No oral artemisinin monotherapy was found in public 
health facilities or among VMW in 2011 and 2013.
Anti‑malarial market share
Figure  7 shows the market share of different categories 
of anti-malarials sold or distributed in the 7  days prior 
to the survey over time. Public sector anti-malarial mar-
ket share increased over time from 30 % in 2009 to 40 % 
in 2013. In the private sector, anti-malarial market share 
declined over time from 70 % in 2009, to 60 % in 2013. 
ACT accounted for 72  % of the total market share in 
2009; 52 % in 2011 and 87 % in 2013.
In terms of the market share of the first-line treatment 
in 2009 ASMQ was the most commonly distributed anti-
malarial, with the public sector distributing little else. In 
2011, ASMQ continued to be the most commonly dis-
tributed anti-malarial, with the new first-line DHA-PPQ 
accounting for less than 10 % of the total market share, 
and the majority of this distributed in the public sector. 
Increases in the market share of chloroquine in the pri-
vate sector were also notable, comprising 21.7 % of the 
total market share in 2011. During the 2013 survey, most 
of the ACT either sold or distributed nationally was 
DHA-PPQ (62.8  %). Market share of ASMQ was lower 
than previous rounds (23.4  %). Chloroquine made up 
the largest market share of non-artemisinin therapies, 
accounting for 12.4 % of the market share in 2013, and 
found exclusively in the private sector.
Oral artemisinin monotherapy accounted for 6  % of 
total anti-malarial market share in 2009 and 1 % in 2011, 
but was no longer reportedly sold/distributed in 2013.
Malaria diagnostics
The percentage of anti-malarial stocking outlets with 
malaria blood testing available (RDT or microscopy) 
remained high over time among public health facilities 
(over 80  % in 2009, and over 95  % in 2011 and 2013). 
Among VMW this also increased between 2009 from 
73.6 % to over 92 % in 2011 and 2013. In 2013, over 90 % 
of anti-malarial stocking public health facilities and 
VMW had malaria blood testing available (Fig. 8).
Overall trends in blood testing availability among other 
outlet types suggest lower availability in the private sector 
(2009 = 52.7 %; 2011 = 44.2 %; and 2013 = 54.3 %). How-
ever, in 2013, 85.3 % of anti-malarial stocking private for-
profit facilities, 60.1 % of pharmacies and 50.9 % of drugs 
stores had malaria blood testing available. Only 10 % of 
anti-malarial stocking general retailers had malaria test-
ing available.
Trends in the percentage of anti-malarial stocking 
outlets with malaria microscopy show a slight decline 
in availability over time, with lower levels of availabil-
ity observed in 2013 (<35 %) in both public and private 
sector outlets (Additional file  3). Availability of malaria 
RDT increased among anti-malarial stocking public 
health facilities and VMW between 2009 and 2011 and 
remained high in 2013 (93 and 96 % respectively). RDT 
N for the graph is as follows:
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Fig. 4 Trends in the availability of anti-malarial stocking outlets with ASMQ in stock on the day of the survey
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availability remained moderate (~50  %) among anti-
malarial stocking private outlets with the exception of 
general retailers.
Discussion
Shifts in malaria case management policy and strat-
egy to address anti-malarial drug resistance have been 
successfully implemented within the public and private 
sectors in Cambodia. Data from three nationally-repre-
sentative outlet surveys confirm substantial improve-
ments between 2009–2013 regarding removal of oral 
artemisinin monotherapy, ensuring high availability and 
market share of first-line ACT treatments, and a reduc-
tion in the role of drug shops and general retailers in the 
N for the graphs is as follows:
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Fig. 6 Trends in the availability of anti-malarial stocking outlets with oral artemisinin monotherapy in stock on the day of the survey
N for the above graphs are as follows:
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Fig. 5 Trends in the availability of anti-malarial stocking outlets with DHA-PPQ in stock on the day of the survey
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distribution of anti-malarials relative to other private sec-
tor outlet types such as health facilities and pharmacies. 
The data also illustrate wide spread availability of malaria 
diagnostics for confirmatory testing prior to anti-malarial 
treatment in the public sector, and moderate availability 
in the private sector. The following sub-sections discuss 
these changes in the context of national strategies and 
policies to improve malaria case management practices 
and artemisinin resistance containment efforts over the 
past 5 years in Cambodia.
Oral AMT removal
Significant reductions and removal of oral artemisinin 






























ASMQ DHA-PPQ Other ACT Non-artemisinin therapy Oral artemisinin monotherapy
Fig. 7 Trends in anti-malarial market share (A total of 1828.2, 919.9 and 284.0 AETDs were reportedly sold or distributed in the previous 7 days in 
2009, 2011 and 2013 respectively)
N for the above graph is as follows:
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Fig. 8 Percentage of anti-malarial stocking outlets with malaria blood testing available
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policy changes and successful enforcement and imple-
mentation by Cambodian officials, including the MoH, 
Ministry of Interior, and the Regulatory Agency for 
Drugs and Foods [23]. Historically, artemisinins have 
been available as monotherapies in western Cambodia 
for more than 30 years, in a variety of forms and doses. 
Oral artemisinin monotherapies were notably less expen-
sive than ACT in Cambodia, fueling their market avail-
ability and consumption [24]. It was also estimated that 
in 2007, 78  % of artemisinin use in western Cambodia 
consisted of monotherapy provided through the private 
sector [25]. The 2013 outlet survey shows that no oral 
artemisinin monotherapy was being sold or distributed 
in the week prior to the survey. Measures by the Cam-
bodian government to stop the importation and distri-
bution of oral artemisinin monotherapy and supportive 
and educative activities with private providers of malaria 
treatment were successful.
Availability and distribution of first‑line ACT
High availability and market share for the first-line ACT 
in 2013 reflect effective strategies to implement changes 
in national treatment guidelines. However, 2011 availa-
bility and market share of the first-line treatment is lower, 
particularly in the private sector, and is indicative of con-
siderable challenges regarding the shift from ASMQ to 
DHA-PPQ as the first-line treatment in December 2010. 
These challenges are and discussed in this sub-section.
In 2010, DHA-PPQ became the first-line treatment in 
Cambodia. In 2011, the outlet survey data shows that in 
the public sector, 8 months after the changes to the treat-
ment guidelines, around half of all VMW and one in four 
public health facilities had DHA-PPQ in stock, indicat-
ing relatively rapid changes, but still only moderate avail-
ability. In the private sector, availability and market share 
of DHA-PPQ was substantially lower as compared to the 
public sector. Market share data from 2011 also shows 
an increase in chloroquine distribution as compared to 
data from 2009, and despite the fact that chloroquine was 
removed from the national treatment guidelines in 2000. 
It is only in 2013 that DHA-PPQ becomes the most com-
monly distributed anti-malarial in both the public and 
private sectors.
The reasons for low availability and market share of the 
first-line treatment in 2011 centre around procurement 
regulations pertaining to purchase of medicines using 
international donor funds. When the first-line treat-
ment changed in 2010, two manufacturers were produc-
ing DHA-PPQ. Neither of these manufacturers had good 
manufacturing practice (GMP) or stringent regulatory 
authority (SRA) approvals, both of which are required in 
order to procure anti-malarial medicines under interna-
tional donor regulations. In October 2011, one brand of 
DHA-PPQ, Euratesim®, received SRA approval through 
the European Medicines Agency (EMA) [26] allowing a 
much delayed order to be placed. The 2011 outlet sur-
vey captures this contextual background, illustrating a 
low availability of DHA-PPQ in the public sector, and no 
availability in the private sector. The moderate availability 
in the public sector is explained by efforts by the WHO 
in 2010, who procured DHA-PPQ directly for CNM 
from the second producer. However, the private sector 
was faced with an unprecedented 10 month ACT stock-
out [27]. It was only in July 2012, that 400,000 doses were 
delivered to Cambodia’s private sector [26]. Significant 
shifts in first-line ACT availability in both the public and 
private sectors are therefore only observed in the 2013 
outlet survey, where DHA-PPQ was the most commonly 
distributed anti-malarial nationwide, and chloroquine 
availability and market share had dropped in the private 
sector.
The procurement problems faced in 2010 had detri-
mental effects on malaria control efforts and strategies 
in Cambodia that were beyond the control of the govern-
ment and other national stakeholders. While the WHO 
was able to procure much needed first-line ACT for the 
public sector, the effects were devastating for the private 
sector where over 65 % of patients seek care when they 
suspect they have malaria [14, 15]. This situation dem-
onstrates the fragility of the anti-malarial market, and 
illustrates how constant supply of quality-assured ACT, 
supported by donors, is challenging given the fact that 
there are only few manufacturers with the required regu-
latory approvals. The need to rapidly respond to evolv-
ing drug resistance further compounds the situation, and 
highlights the challenges that in-country stakeholders 
and the government face in executing fast responses on 
the ground.
In its continuing effort to keep one step ahead of drug 
resistance, Cambodia’s national treatment guidelines 
changed again in 2014 and currently stipulate the use 
of both co-formulated ASMQ and DHA-PPQ in differ-
ent parts of the country as first-line drug for treatment 
of uncomplicated malaria. In Cambodia’s situation where 
bespoke, rather than off-the-shelf anti-malarials, the 
MoH and donors may need to consider parallel stocking 
systems whereby two or more anti-malarials are stocked 
in-country to guarantee anti-malarials are immediately 
on-hand depending on the drug resistance, while accept-
ing that drug wastage will be an inevitable reality in the 
drive towards elimination.
Roles and regulation for the private sector
While anti-malarial availability is declining in the private 
sector, private sector outlets are still responsible for sub-
stantial anti-malarial market share indicating this is an 
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important source of treatment for febrile patients. The 
most recent Cambodia malaria survey (2013) also shows 
that over half the population exclusively obtain treat-
ment from the private sector, and up to 40  % first seek 
treatment from outlets such as drug shops, retailer out-
lets and itinerant vendors [14]. The 2009, 2011 and 2013 
outlet surveys show that the performance of the private 
sector over time has improved, with most of these out-
let types distributing the first-line treatment in 2013. It is 
also notable that the private sector market composition 
has shifted over time towards an increasing contribu-
tion from private health facilities and pharmacies, and 
a declining contribution from drug stores and general 
retailer outlets—outlets which typically operate with-
out formal licensing or registration, and are not formally 
regulated.
Active and supportive regulation has also had a key role 
to play in improving the performance of the market for 
malaria treatment. This has included active engagement 
by CNM with the private sector through PSI to ensure 
the availability of high quality first-line ACT treatments 
and RDT in the private sector through social market-
ing techniques. Sales data indicate that PSI is the larg-
est importer and distributor of ACT in the country and 
quite likely one of the largest pharmaceutical distributors 
overall [28]. PSI sales data indicate that in 2009, around 
280,000 ACT doses were distributed and 107,600 in 2013. 
Sales were much lower in 2011 given the aforementioned 
fist-line DHA-PPQ stock-out, with only 64,000 ACT 
doses distributed, and thus explaining some of the drop 
in ACT availability and market share in 2011. In 2009, 
PSI was distributing ACT and RDT to over 1700 out-
lets such as clinics and hospitals, pharmacies, and drug 
stores, which can also serve as wholesalers from which 
other outlets can procure medicines [29]. Tightened 
regulation also meant that only registered outlets were 
allowed to receive ACT and RDT through PSI, perhaps 
helping to explain the overall drop in anti-malarial avail-
ability across different private outlet types, though this 
could also reflect decreasing malaria caseload, lending 
to a disincentive among private providers to stock anti-
malarial medicines.
The changing performance of the private sector is also 
reflected in the increasing number of licensed private 
providers and intensified enforcement and regulatory 
activities in the private health sector [17]. Private outlets 
have been progressively registered since 2011, with over 
2000 private outlets across the country currently regis-
tered by Department of Drugs and Food.
Efforts to engage the private sector also show an 
increase in the number of licensed private provid-
ers under the PPM programme network as a means to 
improve the quality of malaria case management and to 
ensure malaria case load data is reported up to CNM. It 
is promising that under Cambodia’s 2016–2020 malaria 
elimination plan, the PPM programme will be scaled up 
across the 45 malaria endemic ODs to reach all licensed 
providers. The government has plans to map both 
licensed and unlicensed providers. Unlicensed provid-
ers will be encouraged to obtain the required license 
enabling them to be eligible for joining the PPM pro-
gramme, and CNM also plans to strengthen monitoring 
and supervision of the programme and will supply ACT 
and RDT directly to private providers in their implemen-
tation areas. Additionally, there are plans to restrict the 
import or sale of any anti-malarial not recommended as 
per national policy and thus further increasing the avail-
ability and quality of case management services in the 
private sector [2]. Mystery clients may be a particularly 
useful survey method to help to flush out monotherapies 
and other illegal medicines that would have otherwise be 
hidden by providers, given the increase in regulation of 
the private sector outlets. In addition to tightened regula-
tion of the private sector market, efforts must continue to 
engage the general population regarding the appropriate 
sources of treatment for febrile illness.
Confirmatory testing prior to anti‑malarial treatment
Adherence to case management policy stipulating con-
firmatory testing prior to treatment is currently facili-
tated by high availability of malaria blood testing among 
public and private-for-profit health facilities and VMW, 
and moderate availability among pharmacies and drug 
shops. The data also point to a marked increase in RDT 
availability across the different outlet types, including 
public health facilities. In fact, public health facility case-
load data suggested a marked shift from malaria micros-
copy to RDT. Between 2008 and 2010 the number of 
slides taken annually in health facilities decreased from 
88,742 to 82,565. At the same time the number of RDT 
used in public health facilities increased from 46,989 
to 178,364, indicating a shift to reliance on RDT for the 
majority of confirmed diagnoses [27]. This increase may 
also be facilitated by the introduction in 2009 of a Combo 
RDT in the public and private sector, which detects both 
falciparum as well as vivax malaria. VMW, which only 
stock RDT also show significant improvements in RDT 
availability after the expansion in 2009. The importance 
of VMW programme is also reflected in findings from 
a population based survey which suggests that the like-
lihood of a patient receiving an RDT in areas where the 
VMW programme is present increases 11-fold as com-
pared to those areas where the VMW programme is not 
present [25]. Furthermore, it is estimated that VMW 
diagnosed and treated more than half of malaria cases 
recorded in the public sector in 2014 and 100 % of these 
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cases are confirmed by RDT, suggesting the importance 
of maintaining constant supply to these providers.
Observing the private sector, availability of malaria is 
somewhat variable, but overall stocking rates are much 
higher than observed in other ACTwatch countries [30]. 
These findings reflect the recognition and the importance 
of the private sector by the Cambodian government, 
and strategies to manage diagnosis, treatment, and refer 
within this sector. Since 2000, the government policy has 
been to actively promote the use of tests prior to treat-
ment for malaria. Since 2002, the government policy 
has allowed malaria diagnosis using RDT to be intro-
duced into selected private health facilities through the 
social marketing approaches implemented by PSI [28, 
29]. PSI recommends a very low RDT price to encour-
age providers to test every febrile patient, and to incen-
tivise patients to get treated. As such, for over a decade 
the Cambodian private sector has been authorized to 
test, and treat, cases of uncomplicated malaria. In 2009 
over 350,000 RDT were distributed by PSI in the country, 
and over 400,000 in 2010 and 2012, and 475,670 in 2013. 
This collaboration between CNM and PSI has helped to 
ensure the readiness and adherence of the private sector 
to adhere to national guidelines.
Given that one of the cornerstones of malaria elimi-
nation is parasitological confirmation of all suspected 
malaria cases by either microscopy or RDT [31], outlet 
survey results point to the fact that current rates of diag-
nostic availability are sub-optimal among private sector 
anti-malarial stocking outlets, though it is acknowledge 
that RDT availability may be higher among those outlets 
that are part of the PPM programme. Results also suggest 
that anti-malarials continue to be distributed by outlets 
where confirmatory testing is not available in the private 
sector. In support of this, evidence from the Cambodia 
malaria survey in 2013 revealed that only 11 % of febrile 
patients received a confirmatory diagnostic test, suggest-
ing there is widespread need to not only promote the 
availability of tests, but also ensure they are administered 
[32]. These findings point to two issues that relate to 
the success of Cambodia’s immediate elimination strat-
egy in the context of diagnosis. First is the assurance of 
wide spread availability of diagnostic testing to ensure 
100  % parasitological diagnosis of all suspected malaria 
cases by 2016. This may be achieved by tapping into on-
going PPM programme efforts and continued efforts to 
socially market RDT. Second is the need to ensure that 
all patients seeking treatment for fever are tested prior to 
being administered medication. Given the current dis-
connect, there is a need to understand the demand driv-
ers for adoption of diagnosis among health care providers 
in the private sector.
Limitations
Despite the study’s strengths, the ACTwatch outlet sur-
vey data have several limitations, which have been docu-
mented elsewhere in detail [19, 21, 32]. Specific to the 
surveys in Cambodia: (i) providers may have had incen-
tives to mis-report certain information. The ban on the 
sale of oral artemisinin monotherapy and tightened regu-
lation of the private sector may have made providers wary 
to report availability of certain types of anti-malarials, or 
in the case of outlets that had not been licensed, to report 
any availability of anti-malarial medicines. Although 
interviewers stressed that they were not connected with 
any regulatory body, it is acknowledged that anti-malarial 
stocks may have been under-reported as found by others 
using similar census methods [33]. (ii) Data were only col-
lected at three time points over 5 years and estimates of 
availability apply to the survey period. These estimates 
do not reflect the extent to which anti-malarial medicine 
availability fluctuated due to stock-outs that may have 
occured more than 3 months prior to the data collection. 
In addition, given that data were not collected during the 
same time period across the survey rounds, seasonal vari-
ation regarding availability of anti-malarials and volumes 
may be expected. In particular, given that the 2013 data 
were collected towards the end of the malaria season 
from September to October, anti-malarial availability and 
sales volumes may have been lower than as compared to 
the other survey rounds where data collection started in 
June. (iii) While a methodological strength of the survey is 
the full census of outlets in selected clusters, there were a 
number of practical implementation challenges with this 
method. Heavy rains, flooding and difficult terrain made 
it challenging for field workers to conduct a full census 
in the clusters to screen every outlet. (iv) While the study 
addressed key anti-malarial market indicators, assessment 
of drug quality or storage conditions of the anti-malarials 
was not determined. Providing additional information on 
the quality of anti-malarials, as well as the identification of 
any falsified anti-malarials, would have provided a more 
comprehensive view of the anti-malarial landscape. That 
said, recent drug quality evidence collected from Cambo-
dia’s private sector found no falsified medicines, though 
around one in three medicines were deemed poor qual-
ity, and around one tenth were past their expiry date [33]. 
(v) Finally, the outlet survey methodology is most use-
ful for measuring malaria diagnostic testing and medi-
cine availability and relative distribution of anti-malarial 
treatments. However the methodology is less useful for 
measuring appropriate malaria case management for indi-
vidual cases. This includes confirmatory testing for each 
suspected case, prescription based on test results, and 
adherence to full course treatments. Tracking appropriate 
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case management for all suspected malaria cases will be 
important for informing and monitoring progress towards 
malaria elimination in Cambodia.
Conclusion
Multiple drug policy changes and effective enforcement 
strategies have been required in Cambodia to respond to 
artemisinin drug resistance and to drive progress towards 
P. falciparum elimination. These drug policy changes 
have been implemented by public and private sector 
partners with success, including the removal of oral arte-
misinin monotherapy and changes in first-line therapy. 
The vast majority of anti-malarials distributed in Cambo-
dia through public and private outlets are now first-line 
ACT. Adherence to case management policy stipulat-
ing confirmatory testing prior to treatment is currently 
facilitated by high availability of malaria blood testing 
among public and private health facilities and VMW 
and moderate availability among pharmacies and drug 
shops. Continued implementation of successful public 
and private sector strategies in support of evolving drug 
policies will be important to protect the efficacy of anti-
malarial medicines and ultimately facilitate P. falciparum 
elimination in Cambodia. Ensuring full access to quality 
diagnosis and treatment services among private sector 
providers will be essential to the country’s elimination 
efforts. Overcoming procurement bottlenecks will allow 
the country to respond rapidly to emerging drug resist-
ance by facilitating the immediate availability of malaria 
first-line treatment. Future ACTwatch outlet surveys in 
Cambodia, as well as Laos, Thailand, Myanmar and Viet-
nam will provide standardized measures of anti-malarial 
market composition, readiness and performance for 
appropriate case management. This evidence will con-
tribute towards building an enabling environment at 
national, regional and global levels for progress towards 
malaria elimination.
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